Med-Tech Innovation April 10, 2024
The multi-award-winning University of Exeter spinout company, Neuronostics, has raised 2.1 million GBP in funding to develop its epilepsy diagnosis technology. The successful round of seed funding was led by the Ascension Life Fund.
The new investment, along with backing from a group of additional investors including QantX, the Cornwall and Isles of Scilly Investment Fund managed by The FSE Group and Empirical Ventures, will allow Neuronostics to accelerate its route to market in the UK and Middle East, while also seeking regulatory approval from the FDA for the US market.
Chris Wheatcroft, Investment Director at the Ascension Life Fund said: “We are delighted to have invested in Neuronostics, whose software as a medical device could revolutionise how neurological conditions...
Today's Sponsors
Today's Sponsor